Recent advances in the biology of germcell tumors

Implications for the diagnosis and treatment

P. Chieffi, S. Chieffi, R. Franco, A. A. Sinisi

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Testicular germ cell tumors (TGCT), are the most frequent solid malignant tumors in men 20-40 yr of age, and the most frequent cause of death from solid tumors in this age group. TGCT can be subdivided into seminoma and nonseminoma germ cell tumors (NSGCT), including embryonal cell carcinoma, choriocarcinoma, yolk sac tumor, and teratoma. Seminomas and NSGCT do not only present distinctive clinical features, but they also show significant differences as far as therapy and prognosis are concerned. Many novel markers have given further advantages to discriminate between histological subgroups. In addition, therapeutic approaches for the treatment of TGCT have been proposed: humanized antibodies against receptors/surface molecules on cancer cells, inhibitors of serine-threonine, and tyrosine kinases, and others. The review will focus on the recent advances in the research of molecular alterations identified in TGCT and on novel targeted anti-neoplastic strategies that might help to treat chemotherapy-resistant TGCT.

Original languageEnglish
Pages (from-to)1015-1020
Number of pages6
JournalJournal of Endocrinological Investigation
Volume35
Issue number11
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Seminoma
Germ Cell and Embryonal Neoplasms
Neoplasms
Endodermal Sinus Tumor
Embryonal Carcinoma Stem Cells
Therapeutics
Antibodies, Monoclonal, Humanized
Choriocarcinoma
Protein-Serine-Threonine Kinases
Teratoma
Protein-Tyrosine Kinases
Cause of Death
Age Groups
Testicular Germ Cell Tumor
Drug Therapy
Research

Keywords

  • Aurora B
  • Gonocytes
  • GPR30
  • HMGA
  • PATZ1
  • Seminoma
  • Teratoma
  • Testicular cancer
  • Testicular germ cells tumors
  • Testis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Recent advances in the biology of germcell tumors : Implications for the diagnosis and treatment. / Chieffi, P.; Chieffi, S.; Franco, R.; Sinisi, A. A.

In: Journal of Endocrinological Investigation, Vol. 35, No. 11, 12.2012, p. 1015-1020.

Research output: Contribution to journalArticle

Chieffi, P. ; Chieffi, S. ; Franco, R. ; Sinisi, A. A. / Recent advances in the biology of germcell tumors : Implications for the diagnosis and treatment. In: Journal of Endocrinological Investigation. 2012 ; Vol. 35, No. 11. pp. 1015-1020.
@article{fd3f6a930e4941a6ad6aa1630409abb3,
title = "Recent advances in the biology of germcell tumors: Implications for the diagnosis and treatment",
abstract = "Testicular germ cell tumors (TGCT), are the most frequent solid malignant tumors in men 20-40 yr of age, and the most frequent cause of death from solid tumors in this age group. TGCT can be subdivided into seminoma and nonseminoma germ cell tumors (NSGCT), including embryonal cell carcinoma, choriocarcinoma, yolk sac tumor, and teratoma. Seminomas and NSGCT do not only present distinctive clinical features, but they also show significant differences as far as therapy and prognosis are concerned. Many novel markers have given further advantages to discriminate between histological subgroups. In addition, therapeutic approaches for the treatment of TGCT have been proposed: humanized antibodies against receptors/surface molecules on cancer cells, inhibitors of serine-threonine, and tyrosine kinases, and others. The review will focus on the recent advances in the research of molecular alterations identified in TGCT and on novel targeted anti-neoplastic strategies that might help to treat chemotherapy-resistant TGCT.",
keywords = "Aurora B, Gonocytes, GPR30, HMGA, PATZ1, Seminoma, Teratoma, Testicular cancer, Testicular germ cells tumors, Testis",
author = "P. Chieffi and S. Chieffi and R. Franco and Sinisi, {A. A.}",
year = "2012",
month = "12",
doi = "10.3275/8716",
language = "English",
volume = "35",
pages = "1015--1020",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "11",

}

TY - JOUR

T1 - Recent advances in the biology of germcell tumors

T2 - Implications for the diagnosis and treatment

AU - Chieffi, P.

AU - Chieffi, S.

AU - Franco, R.

AU - Sinisi, A. A.

PY - 2012/12

Y1 - 2012/12

N2 - Testicular germ cell tumors (TGCT), are the most frequent solid malignant tumors in men 20-40 yr of age, and the most frequent cause of death from solid tumors in this age group. TGCT can be subdivided into seminoma and nonseminoma germ cell tumors (NSGCT), including embryonal cell carcinoma, choriocarcinoma, yolk sac tumor, and teratoma. Seminomas and NSGCT do not only present distinctive clinical features, but they also show significant differences as far as therapy and prognosis are concerned. Many novel markers have given further advantages to discriminate between histological subgroups. In addition, therapeutic approaches for the treatment of TGCT have been proposed: humanized antibodies against receptors/surface molecules on cancer cells, inhibitors of serine-threonine, and tyrosine kinases, and others. The review will focus on the recent advances in the research of molecular alterations identified in TGCT and on novel targeted anti-neoplastic strategies that might help to treat chemotherapy-resistant TGCT.

AB - Testicular germ cell tumors (TGCT), are the most frequent solid malignant tumors in men 20-40 yr of age, and the most frequent cause of death from solid tumors in this age group. TGCT can be subdivided into seminoma and nonseminoma germ cell tumors (NSGCT), including embryonal cell carcinoma, choriocarcinoma, yolk sac tumor, and teratoma. Seminomas and NSGCT do not only present distinctive clinical features, but they also show significant differences as far as therapy and prognosis are concerned. Many novel markers have given further advantages to discriminate between histological subgroups. In addition, therapeutic approaches for the treatment of TGCT have been proposed: humanized antibodies against receptors/surface molecules on cancer cells, inhibitors of serine-threonine, and tyrosine kinases, and others. The review will focus on the recent advances in the research of molecular alterations identified in TGCT and on novel targeted anti-neoplastic strategies that might help to treat chemotherapy-resistant TGCT.

KW - Aurora B

KW - Gonocytes

KW - GPR30

KW - HMGA

KW - PATZ1

KW - Seminoma

KW - Teratoma

KW - Testicular cancer

KW - Testicular germ cells tumors

KW - Testis

UR - http://www.scopus.com/inward/record.url?scp=84871903216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871903216&partnerID=8YFLogxK

U2 - 10.3275/8716

DO - 10.3275/8716

M3 - Article

VL - 35

SP - 1015

EP - 1020

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 11

ER -